Home > Healthcare > Drug Device Combination > Therapeutic Systems > Hydronephrosis Treatment Market

Hydronephrosis Treatment Market Trends

Report ID: GMI8524
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Hydronephrosis Treatment Market Trends

Increasing adoption of advanced medical imaging techniques for diagnosis is anticipated to propel the market growth over the analysis period. Adoption of MRI and CT scans for diagnostic procedures is significantly impacting medical practices globally.

Advanced imaging techniques, such as Magnetic Resonance Urography (MRU), offer significant advantages in the diagnosis and treatment of hydronephrosis. MRU has been shown to have high sensitivity and specificity for detecting and grading hydronephrosis, as well as identifying the location of obstruction when present. This accuracy makes MRU a valuable tool in diagnosing and monitoring hydronephrosis.
Additionally, CT scans with special dose-reduced protocols are increasingly gaining importance in detecting calcified stones. By applying dose reduction algorithms, the effective radiation dose can be significantly reduced, making it safer for patients while maintaining diagnostic accuracy. Due to such advantages the need for diagnosis procedures for hydronephrosis is rising.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global hydronephrosis treatment industry was valued at around USD 2.4 billion in 2023 and is expected to reach around USD 4.9 billion by 2032, driven by the growing prevalence of kidney diseases.

Intrinsic indication segment held leading revenue share in 2023 and is anticipated to reach USD 3.4 billion by 2032, driven by the growing incidence of conditions such as kidney stones, urinary tract infections (UTIs), benign prostatic hyperplasia (BPH), and pelvic tumors.

North America hydronephrosis treatment industry accounted for around USD 1 billion in 2023 and is predicted to witness substantial growth through 2032, driven by a well-developed healthcare infrastructure, with access to state-of-the-art medical technology and expertise.

AbbVie Inc, Amgen Inc, The Anthem Group, F. Hoffmann-La Roche Ltd, Nephrogenex Inc., Novartis AG, Pfizer Inc., Phraxis Inc., Renal Associates P.A., and Sanofi are some of the major industry contenders.